CannabisNewsWire
CannabisNewsWire

News and publishing service
for cannabis related companies

LimeLight of The week is


India Globalization Capital Inc.
(NYSE American: IGC)

View The Complete Profile

India Globalization Capital Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule (www.clinicaltrials.gov). As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Investment Considerations

  • IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia.
  • As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC based formulation on Alzheimer’s patients.
  • The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines.
  • Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S.
View More





Recent Coverage

InvestorNewsBreaks - India Globalization Capital Inc. (NYSE American: IGC) Set to Begin IGC-AD1 Phase 2 Trials at Sites Throughout Canada

India Globalization Capital (NYSE American: IGC) today announced its receipt of a no objection letter from Health Canada for approval of its “Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer’s Disease.” The letter provides the acknowledgement of IGC-AD1’s drug candidacy and the authority to proceed with phase 2 trials in Canada. “We are pleased to have received this no objection letter from Health Canada, which allows us to begin phase 2 trials on our drug formulation IGC-AD1 at sites throughout Canada,” said Ram Mukunda, CEO of IGC. “We already have one testing site signed up in Canada, bringing our total number of sites to three, and we are currently in negotiations for several more sites in Florida, Maryland and Montreal. This will also allow us to recruit a diverse population that reflects the demographics of the disease. Receiving this approval is a milestone in our progress towards gaining FDA approval and increases the number of patients with Alzheimer’s that we can enroll. We now have access to several additional locations, including the USA, for our team to safely and efficiently test the efficacy of IGC-AD1 for the treatment of agitation in dementia due to Alzheimer’s disease.”

To view the full source article, visit: https://ibn.fm/eT3IY

Receive SMS Text Alerts from CannabisNewsWire

Text "Cannabis" to 844-397-5787

(US Mobile Phones Only)

Featured Event
 

The Lift & Co. Expo
January 12-14, 2023 - Vancouver, BC

The Lift & Co. Expo invites businesses, growers, patients, and leaders of the cannabis community to its Lift& Co. Expo Vancouver on January 12-14, 2023. The Canadian community participates in the Lift& Co Expo in growing numbers as the event offers immense networking opportunities and valuable education on the latest topics that buzz in the cannabis industry.

Thought leaders and industry veterans will preside as speakers offering insights about important industry trends and technology, and introducing the latest businesses and products. Capital investors can explore the potential of new products to establish a hold over the cannabis market before other vendors do.

The Cannabis Business Conference will be attended by cannabis dignitaries who will discuss a range of important topics, and offer presentations on the latest issues and trends in Canada’s cannabis industry.

Connect with the industry leaders, experts, innovators, regulators, and enthusiasts of the cannabis business community at North America’s leading cannabis conference and trade show in Vancouver.

To know more, please visit https://ibn.fm/J28rO

Conference Highlights

  • The Canadian cannabis community and enthusiasts worldwide are invited to attend its Lift& Co. Expo Vancouver on January 12-14, 2023
  • The Lift Business Conference is an additional part of the 3-day Lift & Co. Expo 2022 that is being held at the Vancouver Convention Centre
  • Exhibitors will showcase unique cannabis products and ideas at their booths where investors can discover potential investment ideas
View Event


Upcoming Events

View All Events

About CannabisNewsWire (CNW)

CannabisNewsWire (CNW) is a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. Leveraging a professional team of journalists and writers, CNW introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network of over 5,000 key distribution outlets. Cutting through information overload, CNW's innovative and proprietary systems clearly and succinctly deliver its clients much needed visibility, recognition and brand awareness. CNW is where news, content and information converge.

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.cannabisnewswire.com/disclaimer/

Stay Informed
We will be posting information about the presenting companies as they take the stage.

See The Latest

Connect With Us
Follow us on social media for the latest news and information from our network of brands and clients.

follow us on twitter  meet on linkedin  like us on facebook

CannabisNewsWire

CannabisNewsWire
303 S Broadway, Denver, CO 80209 (303) 498-7722


Copyright © 2019. All Rights Reserved.